BALTIMORE–(BUSINESS WIRE)–Sep 22, 2021–
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Firm”), a scientific stage pharmaceutical firm dedicated to extending wholesome lifespan, at the moment introduced new knowledge demonstrating Supera-CBD’s superior efficiency over CBD by issue of 8,000 instances. Supera-CBD is MyMD’s pre-clinical patented artificial cannabidiol (CBD) spinoff that’s being developed as a pharmaceutical drug to handle anxiousness, ache, and neurodegeneration. The examine was performed by Eurofins Discovery, a Eurofins Scientific (EUFI.PA) firm.
Supera-CBD targets the cannabinoid receptor sort 2 (CB2), a protein primarily expressed within the immune system and which is related to the therapeutic results of CBD, together with its anxiolytic, anticonvulsant, antipsychotic, neuroprotective and anti inflammatory properties. CB2 receptors don’t create an intoxicating adverse psychotropic response (e.g. a excessive). In distinction, CB1 is often expressed within the mind and distributed all through the central nervous system to ship an intoxicating impact. A overwhelming majority of CBD builders are pursuing compounds focused to CB2 which have minimal CB1 affinity. Watch how Supera-CBD works.
“We imagine that the brand new knowledge we’re revealing at the moment is a rare achievement within the discipline of pharmaceutical cannabinoids,” stated Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD. “We already knew from earlier pre-clinical research performed by a serious medical faculty that Supera-CBD presents a dramatically increased binding affinity for the CB2 receptor as in contrast with plant-derived CBD – an element of 4 instances. However what occurs after binding is what’s most vital to the efficacy of CBD. As soon as the CBD binds to CB2, it should activate the receptor as a way to impact its motion as a therapeutic agent. The brand new knowledge demonstrates what we imagine to be the strikingly efficient means of Supera-CBD to bind to and activate CB2 to probably ship a particularly potent therapeutic profit at a really low non-toxic dose.
“Our drug candidate, with low CB1 affinity and four-fold elevated CB2 binding, is 8,000 instances stronger a CB2 agonist (activator) than common CBD,” Dr. Kaplin continued. “As we’re working to make Supera-CBD a serious worth creator for our shareholders shifting ahead, we couldn’t be extra excited a couple of analysis discovery of this magnitude at this stage of growth.”
Compared to Supera-CBD, the artificial cannabinoid CP 55940, one other extremely potent activator of CB2, can be a extremely potent activator of CB1, delivering an intoxicating impact to the consumer. Because of this, the compound was deserted by its developer and by no means marketed. Supera-CBD is estimated by MyMD to be between 40 to 500 instances the efficiency of the primary found and best-characterized endocannabinoids anandamide and 2-arachidonoyl glycerol, that are produced naturally contained in the physique.
Plant-derived CBD has virtually no exercise on the CB2 receptor, and due to this fact has practically zero efficiency as a medicinal drug.
Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD, acknowledged, “Constructing on CBD’s huge pre-existing market acceptance and the FDA’s declared receptiveness to shifting ahead on this area, we imagine that Supera-CBD can turn into not solely a prescription drug different to unregulated CBD, however the pinnacle of the cannabinoid panorama. At 8,000 instances the efficiency of standard CBD, we imagine that Supera-CBD exhibits robust potential as a therapeutic for high-threat ailments and circumstances like Alzheimer’s, psychosis, neuropathic ache, habit, and anxiousness. The markets for these indications are large, and given Supera-CBD’s excessive efficiency with minimal toxicity, manufacturing prices for very small but extremely efficient doses can be low. Given the exceptional knowledge we’re saying at the moment, we’re optimistic that the long run alternative for our artificial CBD drug candidate is big. We stay up for offering persevering with updates as we advance this drug candidate within the clinic.”
Dr. Kaplin will ship an oral presentation of the brand new Supera-CBD knowledge at the moment on the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. His presentation, “Artificial Superactive Supera-CBD Supersedes CBD,” might be delivered earlier than a prestigious viewers of skilled scientists, thought leaders, and delegates representing premier establishments and firms worldwide.
Supera-CBD is at the moment on a path towards human scientific trials as a remedy for epilepsy, adopted by power ache.
About MyMD Prescription drugs, Inc.
MyMD Prescription drugs, Inc. (Nasdaq: MYMD), a scientific stage pharmaceutical firm dedicated to extending wholesome lifespan, is concentrated on growing two novel therapeutic platforms that deal with the causes of illness and decline quite than solely addressing the signs. MYMD-1 is a drug platform primarily based on a scientific stage small molecule that regulates the immunometabolic system to manage TNF-α, a driver of power irritation, and different pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to deal with growing old and longevity, autoimmune ailments, and COVID-19-associated despair and cytokine elevation. The Firm’s second drug platform, Supera-CBD, is being developed to deal with power ache, habit and epilepsy. Primarily based on a novel artificial spinoff of cannabidiol (CBD), Supera-CBD is being developed to handle the quickly rising CBD market, which incorporates each FDA authorised medicine and CBD merchandise not at the moment regulated as medicine. For extra info, go to www.mymd.com.
Cautionary Assertion Concerning Ahead-Trying Statements
This press launch might comprise forward-looking statements. These forward-looking statements contain recognized and unknown dangers, uncertainties and different components which can trigger precise outcomes, efficiency or achievements to be materially totally different from any anticipated future outcomes, efficiency, or achievements. Ahead-looking statements converse solely as of the date they’re made and none of MyMD nor its associates assume any responsibility to replace forward-looking statements. Phrases corresponding to “anticipate,” “imagine,” “might,” “estimate,” “count on,” “might,” “plan,” “will,” “would” and different related expressions are meant to establish these forward-looking statements. Essential components that would trigger precise outcomes to vary materially from these indicated by such forward-looking statements embody, with out limitation: the timing of, and MyMD’s means to, receive and keep regulatory approvals for scientific trials of MyMD’s pharmaceutical candidates; the timing and outcomes of MyMD’s deliberate scientific trials for its pharmaceutical candidates; the quantity of funds MyMD requires for its pharmaceutical candidates; elevated ranges of competitors; adjustments in political, financial or regulatory circumstances typically and within the markets through which MyMD operates; MyMD’s means to retain and appeal to senior administration and different key workers; MyMD’s means to rapidly and successfully reply to new technological developments; MyMD’s means to guard its commerce secrets and techniques or different proprietary rights, function with out infringing upon the proprietary rights of others and forestall others from infringing on MyMD’s proprietary rights; and the affect of the continuing COVID-19 pandemic on MyMD’s outcomes of operations, marketing strategy and the worldwide economic system. A dialogue of those and different components with respect to MyMD is ready forth within the Quarterly Report on Kind 10-Q for the quarterly interval ended June 30, 2021, filed by MyMD on August 16, 2021. Ahead-looking statements converse solely as of the date they’re made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20210922005168/en/
CONTACT: Investor Contact:
KEYWORD: MARYLAND UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: MyMD Prescription drugs, Inc.
Copyright Enterprise Wire 2021.
PUB: 09/22/2021 11:00 AM/DISC: 09/22/2021 11:02 AM